GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria," The Wall Street Journal, August 4, 2010Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs' " Daily Finance, August 6, 2010 (primary source)
No animal studies have been reported. No application has been made for human clinical trials.
References